Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dme.13201 This article is protected by copyright. All rights reserved. Received Date : 29-Apr-2016 Revised Date : 06-Jul-2016 Accepted Date : 08-Aug-2016 Article type : Research Article Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus Short title: Methylglyoxal and nephropathy in Type 2 diabetes T. M. Jensen 1 , D. Vistisen 1 , T. Fleming 2 , P. P. Nawroth 2 , P. Rossing 1 , M. E. Jørgensen 1,5 , T. Lauritzen 3 , A. Sandbæk 3 and D. R. Witte 3,4 1 Steno Diabetes Center, Gentofte, Denmark, 2 Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany, 3 National Institute of Public Health, Southern Denmark University, Odense, 4 Department of Public Health, Faculty of Health Sciences, Aarhus University, Aarhus and 5 Danish Diabetes Academy, Odense, Denmark Correspondence to: Troels Mygind Jensen. Email: TMYJ@steno.dk What’s new? • In this study, the glucose-derived metabolite methylglyoxal was found to be associated with changes in kidney function. • This is one of the largest studies with methylglyoxal data (n ~ 1400) obtained within a clinical setting (well-characterized population of people with screen-detected Type 2 diabetes mellitus).